Search Results
Jan 08, 2026, 08:25 ET Immorta Bio Doubles Mouse Lifespan Using Combination Senolytic and Regenerative Therapy in Validated Aging Models
(SASP) markers, including IL-11, YKL-40, IL-6, and IL-23RStrong upregulation of regenerative and rejuvenation biomarkers, including Klotho, FGF-2, neo-VEGF, and GDF-11Significant improvement in liver function, with reduced AST and ALTMeaningful improvements in physical
More news about: Immorta Bio Inc.
Jan 06, 2026, 07:19 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis
remaining patients continued their initial treatment with ruxolitinib. CK0804 responders demonstrated decreased circulating levels of TGFβ1, TGFβ2, FGF, PDGF, and sCD40L, reduced plasma and bone marrow monocytes, and normalization of the bone marrow myeloid‑to‑erythroid ratio.About CK0804CK0804
More news about: Cellenkos, Inc.
Dec 10, 2025, 08:52 ET Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
reduction in total symptom burden was observed in 78% of patients (9 of 11).Biomarker profile: Clinical responses correlated with reductions in FGF, sCD40L, PDGF‑AA, and PDGF‑AA/BB.Thrombocytopenic subgroup: All three thrombocytopenic patients tolerated the intensive CK0804 regimen; all
More news about: Cellenkos, Inc.
Dec 01, 2025, 08:00 ET Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
SURF302 for IR NMIBC, SURF303 for LG-UTUC and potentially mUC. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Nov 20, 2025, 06:30 ET NASH/MASH Treatment Market to Surpass USD 31.76 Billion by 2033 as First-in-Class Drugs Redefine Fatty Liver Disease Management | According to DataM Intelligence
More than 80% of late-stage pipeline candidates are metabolic and fibrotic-targeted therapies-ranging from GLP-1 agonists, FGF21 analogues, PPAR agonists, THR-β agonists, ACC inhibitors, and dual agonists-positioning the MASH landscape for unprecedented transformation between
More news about: DataM Intelligence 4 Market Research LLP
Nov 12, 2025, 16:05 ET Tyra Biosciences Announces Participation at Upcoming Investor Events
(LG-UTUC) and potentially metastatic urothelial carcinoma (mUC). TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. The SURF431 study continues to enroll and dose adults with hepatocellular carcinoma (HCC) and other solid tumors with activating FGF/FGFR pathway aberrations. We believe TYRA-430 has the potential to address
More news about: Tyra Biosciences
Nov 04, 2025, 14:00 ET CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025
CIR-0602K alone and in combination tirzepatide triples expression of FGF-21 in WAT Corroborates with results from Phase 2b EMMINENCE
More news about: Cirius Therapeutics
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRA), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate
More news about: Eisai Inc.
Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
residue within the DNA-binding domain of PAX8, disrupting transcriptional activity and reducing the expression of downstream oncogenic targets including FGF18 and CCNA2. In biochemical and cellular assays, the compound showed dose-dependent inhibition of DNA binding in EMSA and selective suppression of PAX8-driven
More news about: BridGene Biosciences
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRA), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate
More news about: Eisai Inc.
Oct 01, 2025, 11:04 ET BioMarin apresenta novos dados que reforçam sua liderança em saúde óssea na reunião anual da Sociedade Americana de Pesquisa Óssea e Mineral
FGFR3.2 O crescimento ósseo é regulado por vários processos biológicos, incluindo vias de sinalização através do fator de crescimento de fibroblastos (FGF, que retarda o crescimento ósseo) e do peptídeo natriurético tipo C (CNP, que aumenta o crescimento ósseo).3 Na acondroplasia, esses sinais
More news about: BioMarin